Etripamil

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C27H36N2O4
Molecular Weight	452.5857
Optical Activity	( - )
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC(=O)C1=CC=CC(CCN(C)CCC[C@](C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)=C1

InChI

InChIKey=VAZNEHLGJGSQEL-MHZLTWQESA-N

InChI=1S/C27H36N2O4/c1-20(2)27(19-28,23-11-12-24(31-4)25(18-23)32-5)14-8-15-29(3)16-13-21-9-7-10-22(17-21)26(30)33-6/h7,9-12,17-18,20H,8,13-16H2,1-6H3/t27-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.milestonepharma.com/research-development/etripamil/

Etripamil is a non-dihydropyridine, L-type calcium channel blocker. Currently, etripamil is in Phase 3 development for the treatment of paroxysmal supraventricular tachycardia. Milestone Pharmaceuticals is also developing etripamil to provide rapid heartbeat control for patients living with atrial fibrillation and acute symptom relief for patients with angina.

Originator

Approval Year

PubMed

Title	Date	PubMed
High-density mapping of the slow pathway in a patient with atrioventricular nodal reentry given intranasal Etripamil during the NODE-1 study.	2017 Oct	29062702
Etripamil: Self-management of supraventricular tachycardia is not far away?	2019 Mar	30627628

Sample Use Guides

In Vivo Use Guide

Phase II study: Etripamil via 4 intranasal applications (140 mg, 105 mg, 70 mg, or 35 mg)

Route of Administration: Nasal

Name

Type

Language

Etripamil

Official Name

English

MSP-2017

Code

English

Methyl 3-[2-[[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]methylamino]ethyl]benzoate

Systematic Name

English

ETRIPAMIL [USAN]

Common Name

English

Benzoic acid, 3-[2-[[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]methylamino]ethyl]-, methyl ester

Systematic Name

English

Etripamil [WHO-DD]

Common Name

English

etripamil [INN]

Common Name

English

(-)-MSP-2017

Code

English

Code System Code Type Description

FDA UNII

S82A18Y42P